

DBL Report

Issue #146 | September 2025

An Official Accompaniment to the *Alberta Drug Benefit List (ADBL)* produced by Alberta Blue Cross®

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS

Margaret Gray, BSP, FCSHP (Chair)
Micheal Guirguis, BScPharm, PhD (Vice-Chair)
Monica Behl, BSP, MD
Morgan Bharadia, BSc Pharm, RPh, PhD
Caitlin A. Clarke, BScPhm, PharmD
Augustine Ezugwu, BPharm, MPH
Ling Ling, BMSc, MD, FRCPC
Rahul Mehta, BScPharm, MD, FRCPC (GIM), AFC
Nicholas Myers, BSc, MB, BS, MRCGP (UK)

ALBERTA HEALTH LIAISON

Andrea Nagle, BScPharm, LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT

Amina Babar, BSc (Pharm)
Julia Chan, BSc (Pharm), MHA, CHE
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Stephanie Parcasio, BSc (Pharm)

The following are highlights of recent changes to the *ADBL* and other topics of general interest. Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable) [DBL Publications | Alberta.ca](#).

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on July 22, 2025. The Committee reviewed Manufacturer submissions for six (6) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments related to the coverage status of twenty-seven (27) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, nineteen (19) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective August 1, 2025, and fifteen (15) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective September 1, 2025.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>

Highlights of Products Originally Reviewed by Canada's Drug Agency (CDA-AMC)

The following Drug Products were reviewed by CDA-AMC and the Expert Committee and added to the *ADBL*:

EFFECTIVE DATE	PRODUCT DESCRIPTION	LISTING STATUS
August 1, 2025	FERRIPROX MR 1000 MG EXTENDED-RELEASE TABLET (DEFERIPRONE) CHIESI CANADA CORP.	Special Authorization
	VRAYLAR 1.5 MG, 3 MG, 4.5 MG & 6 MG CAPSULES (CARIPRAZINE HYDROCHLORIDE) ABBVIE CORPORATION	Restricted Benefit/Special Authorization
	VYVGART 400 MG/20 ML (20 MG/ML) VIAL INJECTION (EFGARTIGIMOD ALFA) ARGENX CANADA INC.	Special Authorization-generalized Myasthenia Gravis (gMG)
	WAINUA 45 MG/0.8 ML AUTOINJECTOR (EPLONTERSEN SODIUM) ASTRAZENECA CANADA INC.	Special Authorization
September 1, 2025	BIMZELX 160 MG/ML AUTO-INJECTOR & INJECTION SYRINGE (BIMEKIZUMAB) UCB CANADA INC.	Special Authorization - Ankylosing Spondylitis (AS)
	BIMZELX 160 MG/ML AUTO-INJECTOR & INJECTION SYRINGE (BIMEKIZUMAB) UCB CANADA INC.	Special Authorization - Psoriatic Arthritis (PsA)
	BIMZELX 320 MG/2 ML AUTO-INJECTOR & INJECTION SYRINGE(BIMEKIZUMAB) UCB CANADA INC.	Special Authorization-PsA & Plaque Psoriasis (PsO)
	IMCIVREE 10 MG/ML INJECTION (SETMELANOTIDE ACETATE) RHYTHM PHARMACEUTICALS INC.	Special Authorization
	VELSIPITY 2 MG TABLET (ETRASIMOD) PFIZER CANADA ULC	Special Authorization



©*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ®† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. G0001-03-25 2025/03

Highlights of Drug Products Added to the ADBL

The following Products were added to the ADBL:

EFFECTIVE DATE	PRODUCT DESCRIPTION	DETAILS	LISTING STATUS
August 1, 2025	JAMP METHOTREXATE 10 MG TABLET (METHOTREXATE) JAMP PHARMA CORPORATION	Establishment of New Interchangeable Groupings (IC Groupings)	Regular Benefit
August 1, 2025	NANOSALV CATALYTIC ADV WOUND CARE TREATMENT MATRIX (N/A) NANOTESS CATALYTIC SOLUTIONS	Device	Regular Benefit
September 1, 2025	COLISTIMETHATE 150 MG/VIAL INJECTION (COLISTIMETHATE SODIUM) MARCAN PHARMACEUTICALS INC.	Single Source Drug Product	Regular Benefit

Highlights of Changes to the ADBL

The following Drug Products on the ADBL incurred changes:

EFFECTIVE DATE	PRODUCT DESCRIPTION	UPDATES
September 1, 2025	BIMZELX 160 MG/ML AUTO-INJECTOR & INJECTION SYRINGE (BIMEKIZUMAB) UCB CANADA INC.	Special Authorization Criteria Change for the indication of PsO due to the addition of Bimzelx 320 mg/2 mL prefilled syringe and auto-injector.



©*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ®† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. GO001-03-25 2025/03